Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients

Emilio Bajetta, Elena Beretta, Maria Di Bartolomeo, Diego Cortinovis, Erminia Ferrario, Giuseppina Dognini, Luisa Toffolatti, Roberto Buzzoni

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives: As single agents, irinotecan and oxaliplatin are active in colorectal cancer after fluorouracil (FU)-containing regimen failure. Their synergistic activity and non-overlapping toxicity profile are well documented, but more data are needed to explore their exact sequence. The aim of this study was to evaluate the activity and tolerability of irinotecan followed by oxaliplatin in patients with FU-resistant colorectal cancer. Methods: FU resistance was defined as disease progression during or within 6 months of discontinuing first-line or adjuvant FU/leucovorin chemotherapy. The study treatment consisted of irinotecan 150 mg/m2 on days 1 and 8 followed by oxaliplatin 85 mg/m2 on day 1 every 3 weeks. In order to improve the safety profile, we changed the schedule during the study to irinotecan 300 mg/m2 on day 1 and oxaliplatin 85 mg/m2on day 2 every 3 weeks. Results: Of 54 patients treated, the 45 patients with measurable disease were assessed in the efficacy analysis, whereas all patients receiving at least one cycle were evaluated in the safety analysis. Of the patients assessed for efficacy analysis, 19 cases received the first schedule and 26 patients received the second schedule. Twenty-two patients (49%) responded, 10 of the first schedule and 12 of the second schedule group. Stable disease was observed in 35% of all patients. The median response duration was 6.5 months (range 3-10), the median time to progression was 8 months (range 6-10), and the overall survival was 15 months (10-26+). The NCI-CTC grade 3 side effects documented in all of the treated patients were: nausea/vomiting (11%), diarrhea (18%), and neutropenia (7%); grade 4 diarrhea was observed in 2% of patients. Conclusion: The combination of irinotecan followed by oxaliplatin combination is well tolerated and highly active in FU-resistant metastatic colorectal cancer patients.

Original languageEnglish
Pages (from-to)132-137
Number of pages6
JournalOncology
Volume66
Issue number2
DOIs
Publication statusPublished - 2004

Fingerprint

oxaliplatin
irinotecan
Fluorouracil
Colorectal Neoplasms
Appointments and Schedules
Diarrhea
Safety

Keywords

  • Fluorouracil resistance
  • Irinotecan
  • Metastatic colorectal cancer
  • Oxaliplatin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients. / Bajetta, Emilio; Beretta, Elena; Di Bartolomeo, Maria; Cortinovis, Diego; Ferrario, Erminia; Dognini, Giuseppina; Toffolatti, Luisa; Buzzoni, Roberto.

In: Oncology, Vol. 66, No. 2, 2004, p. 132-137.

Research output: Contribution to journalArticle

Bajetta, Emilio ; Beretta, Elena ; Di Bartolomeo, Maria ; Cortinovis, Diego ; Ferrario, Erminia ; Dognini, Giuseppina ; Toffolatti, Luisa ; Buzzoni, Roberto. / Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients. In: Oncology. 2004 ; Vol. 66, No. 2. pp. 132-137.
@article{d23d0cf3c1e64e0eb1b92c8d90444321,
title = "Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients",
abstract = "Objectives: As single agents, irinotecan and oxaliplatin are active in colorectal cancer after fluorouracil (FU)-containing regimen failure. Their synergistic activity and non-overlapping toxicity profile are well documented, but more data are needed to explore their exact sequence. The aim of this study was to evaluate the activity and tolerability of irinotecan followed by oxaliplatin in patients with FU-resistant colorectal cancer. Methods: FU resistance was defined as disease progression during or within 6 months of discontinuing first-line or adjuvant FU/leucovorin chemotherapy. The study treatment consisted of irinotecan 150 mg/m2 on days 1 and 8 followed by oxaliplatin 85 mg/m2 on day 1 every 3 weeks. In order to improve the safety profile, we changed the schedule during the study to irinotecan 300 mg/m2 on day 1 and oxaliplatin 85 mg/m2on day 2 every 3 weeks. Results: Of 54 patients treated, the 45 patients with measurable disease were assessed in the efficacy analysis, whereas all patients receiving at least one cycle were evaluated in the safety analysis. Of the patients assessed for efficacy analysis, 19 cases received the first schedule and 26 patients received the second schedule. Twenty-two patients (49{\%}) responded, 10 of the first schedule and 12 of the second schedule group. Stable disease was observed in 35{\%} of all patients. The median response duration was 6.5 months (range 3-10), the median time to progression was 8 months (range 6-10), and the overall survival was 15 months (10-26+). The NCI-CTC grade 3 side effects documented in all of the treated patients were: nausea/vomiting (11{\%}), diarrhea (18{\%}), and neutropenia (7{\%}); grade 4 diarrhea was observed in 2{\%} of patients. Conclusion: The combination of irinotecan followed by oxaliplatin combination is well tolerated and highly active in FU-resistant metastatic colorectal cancer patients.",
keywords = "Fluorouracil resistance, Irinotecan, Metastatic colorectal cancer, Oxaliplatin",
author = "Emilio Bajetta and Elena Beretta and {Di Bartolomeo}, Maria and Diego Cortinovis and Erminia Ferrario and Giuseppina Dognini and Luisa Toffolatti and Roberto Buzzoni",
year = "2004",
doi = "10.1159/000077439",
language = "English",
volume = "66",
pages = "132--137",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "2",

}

TY - JOUR

T1 - Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients

AU - Bajetta, Emilio

AU - Beretta, Elena

AU - Di Bartolomeo, Maria

AU - Cortinovis, Diego

AU - Ferrario, Erminia

AU - Dognini, Giuseppina

AU - Toffolatti, Luisa

AU - Buzzoni, Roberto

PY - 2004

Y1 - 2004

N2 - Objectives: As single agents, irinotecan and oxaliplatin are active in colorectal cancer after fluorouracil (FU)-containing regimen failure. Their synergistic activity and non-overlapping toxicity profile are well documented, but more data are needed to explore their exact sequence. The aim of this study was to evaluate the activity and tolerability of irinotecan followed by oxaliplatin in patients with FU-resistant colorectal cancer. Methods: FU resistance was defined as disease progression during or within 6 months of discontinuing first-line or adjuvant FU/leucovorin chemotherapy. The study treatment consisted of irinotecan 150 mg/m2 on days 1 and 8 followed by oxaliplatin 85 mg/m2 on day 1 every 3 weeks. In order to improve the safety profile, we changed the schedule during the study to irinotecan 300 mg/m2 on day 1 and oxaliplatin 85 mg/m2on day 2 every 3 weeks. Results: Of 54 patients treated, the 45 patients with measurable disease were assessed in the efficacy analysis, whereas all patients receiving at least one cycle were evaluated in the safety analysis. Of the patients assessed for efficacy analysis, 19 cases received the first schedule and 26 patients received the second schedule. Twenty-two patients (49%) responded, 10 of the first schedule and 12 of the second schedule group. Stable disease was observed in 35% of all patients. The median response duration was 6.5 months (range 3-10), the median time to progression was 8 months (range 6-10), and the overall survival was 15 months (10-26+). The NCI-CTC grade 3 side effects documented in all of the treated patients were: nausea/vomiting (11%), diarrhea (18%), and neutropenia (7%); grade 4 diarrhea was observed in 2% of patients. Conclusion: The combination of irinotecan followed by oxaliplatin combination is well tolerated and highly active in FU-resistant metastatic colorectal cancer patients.

AB - Objectives: As single agents, irinotecan and oxaliplatin are active in colorectal cancer after fluorouracil (FU)-containing regimen failure. Their synergistic activity and non-overlapping toxicity profile are well documented, but more data are needed to explore their exact sequence. The aim of this study was to evaluate the activity and tolerability of irinotecan followed by oxaliplatin in patients with FU-resistant colorectal cancer. Methods: FU resistance was defined as disease progression during or within 6 months of discontinuing first-line or adjuvant FU/leucovorin chemotherapy. The study treatment consisted of irinotecan 150 mg/m2 on days 1 and 8 followed by oxaliplatin 85 mg/m2 on day 1 every 3 weeks. In order to improve the safety profile, we changed the schedule during the study to irinotecan 300 mg/m2 on day 1 and oxaliplatin 85 mg/m2on day 2 every 3 weeks. Results: Of 54 patients treated, the 45 patients with measurable disease were assessed in the efficacy analysis, whereas all patients receiving at least one cycle were evaluated in the safety analysis. Of the patients assessed for efficacy analysis, 19 cases received the first schedule and 26 patients received the second schedule. Twenty-two patients (49%) responded, 10 of the first schedule and 12 of the second schedule group. Stable disease was observed in 35% of all patients. The median response duration was 6.5 months (range 3-10), the median time to progression was 8 months (range 6-10), and the overall survival was 15 months (10-26+). The NCI-CTC grade 3 side effects documented in all of the treated patients were: nausea/vomiting (11%), diarrhea (18%), and neutropenia (7%); grade 4 diarrhea was observed in 2% of patients. Conclusion: The combination of irinotecan followed by oxaliplatin combination is well tolerated and highly active in FU-resistant metastatic colorectal cancer patients.

KW - Fluorouracil resistance

KW - Irinotecan

KW - Metastatic colorectal cancer

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=2342469841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342469841&partnerID=8YFLogxK

U2 - 10.1159/000077439

DO - 10.1159/000077439

M3 - Article

VL - 66

SP - 132

EP - 137

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -